We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$767M
1-Year Est. Return
119.71%
This Fund
S&P 500
This Quarter
Est. Return
+30.48%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$621M
AUM Growth
+$72.3M
(+13%)
Cap. Flow
+$31.9M
Cap. Flow
% of AUM
5.14%
Top 10 Holdings %
Top 10 Hldgs %
33.04%
Holding
112
New
30
Increased
19
Reduced
32
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$17.5M |
| 2 |
NVMI
Nova
NVMI
|
+$15.3M |
| 3 |
Global E Online
GLBE
|
+$9.72M |
| 4 |
Taboola.com
TBLA
|
+$6.52M |
| 5 |
Meta Platforms (Facebook)
META
|
+$6.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$6.82M |
| 2 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
+$6.35M |
| 3 |
Amazon
AMZN
|
+$5.55M |
| 4 |
Disc Medicine
IRON
|
+$5.23M |
| 5 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$4.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.14% |
| 2 | Technology | 15.8% |
| 3 | Miscellaneous | 13.36% |
| 4 | Communication Services | 3.76% |
| 5 | Consumer Discretionary | 3.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
101
Disc Medicine
IRON
$2.63B
| – | – |
-111,398
| Closed | -$5.23M |
|
102
Mirum Pharmaceuticals
MIRM
$6.38B
| – | – |
-114,284
| Closed | -$3.61M |
|
103
CALL
Nice
NICE
$6.21B
| – | – |
-105,000
| Closed | -$17.9M |
|
104
PUT
Invesco QQQ Trust
QQQ
$482B
| – | – |
-136,500
| Closed | -$48.9M |
|
105
uniQure
QURE
$3.05B
| – | – |
-148,734
| Closed | -$998K |
|
106
Vera Therapeutics
VERA
$2.44B
| – | – |
-105,000
| Closed | -$1.44M |
|
107
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| – | – |
-50,000
| Closed | -$3.71M |
|
108
Xenon Pharmaceuticals
XENE
$5.52B
| – | – |
-38,959
| Closed | -$1.33M |
|
|
109
PUT
Xenon Pharmaceuticals
XENE
$5.52B
| – | – |
-82,400
| Closed | -$2.81M |
|
|
CALT
110
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
| – | – |
-11,863
| Closed | -$217K |
|
|
PNT
111
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| – | – |
-952,642
| Closed | -$6.35M |
|
Similar funds
ISWM
ACP
NIM
ACM
CBT
SPIA
CNB
HI
Sphera Funds Management's Q4 2023 Portfolio in Review
As of Q4 2023, Sphera Funds Management held 112 positions worth $621M, up 13% from $549M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Sphera Funds Management deployed $31.9M of net new capital in Q4 2023, opening 30 new positions and adding to 19 existing holdings. Its largest new stake was Nova: 132,000 shares worth $18.1M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 61% a quarter earlier, followed by Technology and Miscellaneous.
On the sell side, the largest reduction was AstraZeneca, an estimated $6.82M trimmed.
- Sphera Funds Management's largest Q4 2023 buy was Nova: 132,000 shares worth $18.1M.
- Sphera Funds Management added most to Teva Pharmaceutical Industries Limited in Q4 2023, an estimated $17.5M increase.
- Sphera Funds Management's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $6.82M.
- Sphera Funds Management fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $6.35M.
- Sphera Funds Management's ten largest holdings make up 33% of its $621M portfolio in Q4 2023.
- Sphera Funds Management opened 30 new positions and closed 13 in Q4 2023.
- Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $621M.
Based on Sphera Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.